Of the 13 remaining individuals (six female; mean age, 14.9 years; mean IMD score 4.9), neurodiversity was experienced by two participants with Autism Spectrum Disorder (ASD) or ASD and Attention deficit hyperactivity disorder (ADHD) and seven were receiving a GLP-1 agonist as adjuvant treatment. This evidence concerns the gene GCG and attention deficit-hyperactivity disorder.